TENAX THERAPEUTICS, INC. Preferred Stock Dividends, Income Statement Impact
TENAX THERAPEUTICS, INC. (TENX) reported Preferred Stock Dividends, Income Statement Impact of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2017-03-16
- TENAX THERAPEUTICS, INC. preferred stock dividends, income statement impact for the quarter ending 2015-04-30 was $0.00, a 100.00% decline year-over-year.
- TENAX THERAPEUTICS, INC. preferred stock dividends, income statement impact for the quarter ending 2015-01-31 was $0.00.
- TENAX THERAPEUTICS, INC. preferred stock dividends, income statement impact for the quarter ending 2014-10-31 was $0.00.
- TENAX THERAPEUTICS, INC. preferred stock dividends, income statement impact for the quarter ending 2014-07-31 was $0.00.
- TENAX THERAPEUTICS, INC. preferred stock dividends, income statement impact for fiscal 2016 was $0.00.
- TENAX THERAPEUTICS, INC. preferred stock dividends, income statement impact for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- TENAX THERAPEUTICS, INC. preferred stock dividends, income statement impact for fiscal 2014 was $5.80M, a 505.73% increase from fiscal 2013.
- TENAX THERAPEUTICS, INC. preferred stock dividends, income statement impact for fiscal 2013 was $958.07K.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 3 month as first filed | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 6 month as first filed | Preferred Stock Dividends, Income Statement Impact 8 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 9 month as first filed | Preferred Stock Dividends, Income Statement Impact 12 month | Preferred Stock Dividends, Income Statement Impact 545 month | Preferred Stock Dividends, Income Statement Impact 554 month | Preferred Stock Dividends, Income Statement Impact 557 month |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-03-16 | ||||||||||
| 2015-12-31 | $0.00 10-K · filed 2017-03-16 | ||||||||||
| 2015-04-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $0.00 derived: sum of 2 quarters · filed 2017-03-16 | $0.00 derived: sum of 3 quarters · filed 2017-03-16 | $0.00 10-K · filed 2017-03-16 | |||||||
| 2015-01-31 | $0.00 10-Q · filed 2015-03-17 | $0.00 derived: sum of 2 quarters · filed 2015-03-17 | $0.00 10-Q · filed 2015-03-17 | $11.55M derived: sum of 4 quarters · filed 2017-03-16 | |||||||
| 2014-10-31 | $0.00 10-Q · filed 2014-12-15 | $0.00 10-Q · filed 2014-12-15 | $11.55M derived: sum of 3 quarters · filed 2017-03-16 | $10.45M derived: sum of 4 quarters · filed 2017-03-16 | |||||||
| 2014-07-31 | $0.00 10-Q · filed 2014-09-15 | $11.55M derived: sum of 2 quarters · filed 2017-03-16 | $10.45M derived: sum of 3 quarters · filed 2017-03-16 | $7.90M derived: sum of 4 quarters · filed 2017-03-16 | |||||||
| 2014-04-30 | $11.55M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $10.45M derived: sum of 2 quarters · filed 2017-03-16 | $7.90M derived: sum of 3 quarters · filed 2017-03-16 | $5.80M 10-K · filed 2017-03-16 | |||||||
| 2014-01-31 | -$1.10M 10-Q · filed 2015-03-17 | $1.10M 10-Q · filed 2014-03-17 | -$3.65M derived: sum of 2 quarters · filed 2015-03-17 | -$5.74M 10-Q · filed 2015-03-17 | $5.74M 10-Q · filed 2014-03-17 | -$4.78M derived: sum of 4 quarters · filed 2016-03-14 | $6.70M 10-Q · filed 2014-03-17 | ||||
| 2013-10-31 | -$2.55M 10-Q · filed 2014-12-15 | $2.55M 10-Q · filed 2013-12-17 | -$4.65M 10-Q · filed 2014-12-15 | $4.65M 10-Q · filed 2013-12-17 | -$3.69M derived: sum of 3 quarters · filed 2016-03-14 | -$3.69M derived: sum of 4 quarters · filed 2016-03-14 | $5.60M 10-Q · filed 2013-12-17 | ||||
| 2013-07-31 | -$2.09M 10-Q · filed 2014-09-15 | $2.09M 10-Q · filed 2013-09-17 | -$1.14M derived: sum of 2 quarters · filed 2016-03-14 | -$1.14M derived: sum of 3 quarters · filed 2016-03-14 | -$1.14M derived: sum of 4 quarters · filed 2016-03-14 | $3.05M 10-Q · filed 2013-09-17 | |||||
| 2013-04-30 | $958.07K derived: 10-KT 12 month − 10-Q 9 month · filed 2016-03-14 | $958.07K derived: sum of 2 quarters · filed 2016-03-14 | $958.07K derived: sum of 3 quarters · filed 2016-03-14 | $958.07K 10-KT · filed 2016-03-14 | $958.07K 10-K · filed 2013-06-26 | ||||||
| 2013-01-31 | $0.00 10-Q · filed 2014-03-17 | $0.00 derived: sum of 2 quarters · filed 2014-03-17 | $0.00 10-Q · filed 2014-03-17 | ||||||||
| 2012-10-31 | $0.00 10-Q · filed 2013-12-17 | $0.00 10-Q · filed 2013-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |